Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
[en] With the aim of assessing a new somatostatin analogue to prevent the metabolic changes induced by a 6-h nocturnal arrest of an insulin pump, nine C-peptide negative Type 1 (insulin-dependent) diabetic patients were submitted blindly to two interruptions (from 23.00 to 05.00 hours) of their continuous s.c. insulin infusion, once after a single s.c. injection at 23.00 hours of 50 micrograms SMS 201-995 (Sandostatin, Sandoz) and once after 0.9% NaCl. Plasma SMS 201-995 levels peaked at 24.00 hours and then declined with an elimination half-life averaging 144 +/- 15 min. Plasma glucagon and growth hormone levels were significantly reduced after SMS 201-995 whereas the progressive fall in plasma-free insulin levels from 23.00 to 05.00 hours was unaffected. In the control test, blood glucose levels tended to decrease slightly from 23.00 to 02.00 hours and then increased markedly from 02.00 to 05.00 hours (+5.3 +/- 1.5 mmol/l) while after SMS 201-995 they decreased significantly from 23.00 to 02.00 hours (-2.6 +/- 0.5 mmol/l), resulting in values below 3 mmol/l in seven subjects, but showed a secondary increase until 05.00 hours (+3.5 +/- 1.5 mmol vs 23.00 h; p less than 0.05 vs 0.9% NaCl). While the rises in plasma non-esterified fatty acid and glycerol levels were not reduced by SMS 201-995, the increase in plasma 3-hydroxbutyrate levels, although similar from 23.00 to 02.00 hours, was significantly reduced from 02.00 to 05.00 hours (+77 +/- 20 vs +124 +/- 31 mumols.l-1.h-1; p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Gillet, J.
Rosenthaler, J.
Guiot, J.
Henrivaux, P.
Jandrain, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
Pickup J.C., Keen H., Viberti G.C., White M.C., Kohner E.M., Parsons J.A., Alberti K.G.M.M. (1980) Continuous subcutaneous insulin infusion in the treatment of diabetes mellitus. Diabetes Care 3:290-300.
Sonnenberg G.E., Spraul M., Chantelau E.A., Berger M. (1985) Kontinuierliche subkutane Insulin-Infusionstherapie. Voraussetzungen, Indikationen und Risiken. Dtsch Med Wochenschr 110:1859-1864.
Bending J.J., Pickup J.C., Keen H. (1985) Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Am J Med 79:685-691.
(1984) Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicentre trial. N Engl J Med , Kroc Collaborative Study Group; 311:365-372.
Mecklenburg R., Benson F., Benson J., Fredlund P., Guinn T., Metz R., Nielsen R., Sannar C. (1984) Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA 252:3265-3269.
Peden N.R., Braaten J.T., McKendry J.B.R. (1984) Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion. Diabetes Care 7:1-5.
.
Scheen A.J., Henrivaux P., Jandrain B., Luyckx A.S., Lefèbvre P.J. (1985) Lack of systematic metabolic alterations after a one-hour interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. Diabetes Care 8:621-623.
Scheen A.J., Castillo M., Jandrain B., Krzentowski G., Henrivaux P., Luyckx A.S., Lefèbvre P.J. (1984) Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion. Diabetes Care 7:338-342.
Krzentowski G., Scheen A., Castillo M., Luyckx A.S., Lefèbvre P.J. (1983) A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion. 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 24:314-318.
Scheen A.J., Henrivaux P., Jandrain B., Lefèbvre P.J. (1986) Anti-insulin antibodies and metabolic deterioration after interruption of continuous subcutaneous insulin infusion. Diabetes Care 9:673-674.
Scheen A.J., Krzentowski G., Castillo M., Lefèbvre P.J., Luyckx A.S. (1983) A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion. 2. Marked attenuation of the metabolic deterioration by somatostatin. Diabetologia 24:319-325.
Bauer W., Briner U., Doepfner W., Haler R., Huguenin R., Marbach P., Petcher T.J., Pless J. (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133-1140.
Pless J., Bauer W., Briner U., Doepfner W., Marbach P., Maurer R., Petcher T.J., Reubi J.C., Vonderscher J. (1986) Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroent 21:54-64.
Kutz K., Nuesch E., Rosenthaler J. (1986) Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroent 21:65-72.
Spinas G.A., Bock A., Keller U. (1985) Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care 8:429-435.
Ewing D.J., Borsey D.Q., Bellavere F., Clarke B.F. (1981) Cardiac autonomie neuropathy in diabetes: comparison of measures of R-R interval variation. Diabetologia 21:18-24.
Dole V.P., Meinertz H. (1960) Microdetermination of long chain fatty acids in plasma and tissues. J Biol Chem 235:2595-2599.
Williaon D.H., Mellanby J. (1974) D-(-)-3-hydroxybutyrate. Methods of enzymatic analysis , H.U., Bergmeyer, Verlag Chemie, Weinheim. Academic Press, New York San Francisco London; 1836-1839.
Eggstein M., Kulhmann E. (1974) Triglycérides and glycerol determination after alkaline hydrolysis. Methods of enzymatic analysis, Vol 4 , H.U., Bergmeyer, Academic Press, London; 1825-1831.
Nakagawa S., Nakayama H., Sasaki T., Yoshimo K., Yu Y., Shimozaki K., Aoki S., Mashimo K. (1973) Simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22:590-600.
Heding L.G. (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548.
Christiansen H.A. (1970) A new method for determination of insulin binding immunoglobulins in insulin-treated diabetic patients. Horm Metabol Res 2:187-188.
Schoos R., Schoos-Barbette S., Lambotte C. (1978) Dosage of hemoglobin A1c by isoelectrofocusing. Clin Chim Acta 86:61-65.
del Pozo E., Neufeld M., Schlüter K., Tortosa F., Clarenbach P., Bieder E., Wendel L., Nüesch E., Marbash P., Cramer H., Kerp L. (1986) Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 111:433-439.
Scheen A.J., Gillet J., Guiot J., Henrivaux P., Jandrain B., Lefèbvre P.J. (1986) Attempt to prevent the dawn phenomenon by a bedtime subcutaneous injection of a somatostatin analogue (SMS 201-995) in Type-1 (insulin-dependent) diabetic patients. Diabetologia 29:590-591.
Johnston D.G., Davies R.R., Turner S.J. (1986) Effects of somatostatin and SMS 201-995 on carbohydrate metabolism in normal man. Scand J Gastroent 21:158-165.
Davies R.R., Miller M., Turner S.J., Goodship T.H.J., Cook D.B., Watson M., McGill A., Ørskov H., Alberti K.G.M.M., Johnston D.G. (1986) Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol 24:665-674.
Serrano-Rios M., Navascues I., Saban J., Ordonez A., Sevilla F., del Pozo E. (1986) Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J Clin Endocrinol Metab 63:1071-1074.
MacGorman L.R., Rizza R.A., Gerich J.E. (1981) Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects of both hepatic and extrahepatic tissues in man. J Clin Endocrinol Metab 53:556-559.
Gerich J.E., Lorenzi M., Bier D.M., Tsalikian E., Schneider V., Karam J.H., Forsham P.H. (1976) Effects of physiological levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest 57:875-884.
Johansson C., Wisen O., Efendic J., Uvnas-Wallensten K. (1981) Effects of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 22:126-137.
Willia G., Fuessl H., Kraenzlin M., Bloom S.R. (1986) Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance. Scand J Gastroent 21:73-83.
Rosak C., Althoff P.H., Fassbinder W., del Pozo E., Boehm B.O. (1986) Veränderungen der hormoneilen Gegenregulation nach insulininduzierter Hypoglykämie bei gleichzeitiger Gabe des Somatostatinanalogons SMS 201-995. Med Klin 81:773-778.
McGarry J.D., Foster D.W. (1980) Regulation of hepatic fatty acid oxidation and ketone body production. Ann Rev Biochem 49:395-420.
Schade D.S., Eaton R.P., Peake G.T. (1978) The regulation of plasma ketone body concentration by counterregulatory hormones in man. II. Effect of growth hormone in diabetic man. Diabetes 27:916-924.
Scheen A.J., Henrivaux P., Jandrain B., Lefèbvre P.J. (1987) U-100 insulin gives some protection against metabolic deterioration during CSII interruption. Diabetes Care 10:707-711.
